MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.

Eli Lilly said its once-daily weight loss pill was effective for people with obesity and type 2 diabetes in a key trial, ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will ...

Under brand names like Ozempic and Wegovy, semaglutide-based medications have made a significant difference in treating type ...

SHREVEPORT, La. - A new drug developed by Eli Lily works in a unique way compared to treatments already on the market, like ...

Activation of the human glucagon receptor (GCGR) by its endogenous ligand glucagon triggers the release of glucose from the liver during fasting, making it a potential drug target for type 2 diabetes.